Bryn Anne Boslett, MD

Offices

3 locations · Regents of the University of California · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boslett’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Imperial Courage Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Dynamic Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Senior Value (HMO C-SNP)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026

California Medical Board record

Licence A125322 · Current

Licensed to practise in California · since 2013 · expires 2027-04-30 · Temple University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$26,709

Medicare paid this office $26,709 for 104 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	32	$9,429	$121
Return visit (30+ min)	38	$5,120	$74
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	26	$3,479	$105
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$3,079	$154
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	37	$1,672	$14

See all 8 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	32	$9,429	$121
Return visit (30+ min)	38	$5,120	$74
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	26	$3,479	$105
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$3,079	$154
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	37	$1,672	$14
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	12	$1,387	$116
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	15	$1,261	$70
Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th	14	$596	$27

Who their Medicare patients are

104 Original Medicare patients in 2024. Average age 68 · Under 65 28% · Women 18% · Also on Medicaid 51% · Health risk score 2.37. At or below the middle of the specialty; the typical infectious disease clinician is at 3.

Conditions among them: High blood pressure 75% · Chronic kidney disease 40% · Depression 39% · Diabetes 38% · Coronary heart disease 36% · Atrial fibrillation 28% · Heart failure 26% · Stroke 26% · COPD 22% · Cancer 21% · Dementia 14%.

The office billed $172,506, Medicare allowed $35,500 and paid $26,709; for 386 services of 16 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	104	386	68	2.37	$172,506	$26,709
2023	58	186	68	2.10	$113,601	$16,835
2022	85	183	69	2.48	$120,308	$18,210
2021	38	73	62	1.91	$46,296	$6,330
2020	96	164	69	2.46	$89,133	$11,580
2019	163	288	65	2.87	$198,878	$27,989
2018	119	145	64	2.24	$102,926	$13,288
2017	190	301	61	2.30	$192,105	$27,481
2016	166	321	61	2.64	$191,299	$30,214
2015	74	116	60	2.51	$63,640	$9,183

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	35	$9,085	$115
Return visit (30+ min)	29	$4,396	$79

2022: 4 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	25	$6,214	$117
Initial hospital care with moderate level of medical decision making at least 75 minutes	22	$3,869	$176
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	21	$3,276	$91
Return visit (30+ min)	28	$2,822	$69

2021: 1 service

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	31	$4,715	$107

2020: 5 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	24	$3,167	$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	18	$2,822	$94
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,365	$182
Return visit (30+ min)	16	$1,065	$56
Office for the evaluation and management of established patient that may not require presence of healthcare professional	30	$235	$8

2019: 7 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	50	$8,271	$96
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	30	$4,848	$93
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,354	$181
Return visit (30+ min)	42	$3,088	$61
New patient visit (60+ min)	19	$2,571	$135
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	18	$2,202	$122
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	18	$1,305	$65

2018: 3 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	59	$5,836	$80
New patient visit (60+ min)	16	$2,153	$135
Return visit (30+ min)	18	$1,118	$62

2017: 5 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	66	$7,902	$92
Return visit (30+ min)	71	$6,342	$65
New patient visit (60+ min)	41	$5,610	$137
Initial hospital care with moderate level of medical decision making at least 75 minutes	19	$3,437	$181
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$1,399	$93

2016: 7 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	48	$6,743	$98
Return visit (30+ min)	56	$6,223	$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$5,165	$92
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,285	$179
New patient visit (60+ min)	21	$2,958	$141
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	17	$2,058	$121
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	23	$1,665	$64

2015: 3 services

Sort by

Original Medicare services billed in 2015

Return visit (30+ min)	36	$3,114	$66
Long return visit (40+ min)	14	$1,333	$89
Short return visit (20+ min)	12	$523	$44

Medicaid work

$64,052 in 2024

Medicaid paid $64,052 for 315 billed services this clinician did in 2024, up to 32 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Long return visit (40+ min)	241	$57,454
Service	59	$3,927
Return visit (30+ min)	15	$2,671

Sort by

Medicaid work by year

2024	315	3	32	$64,052
2023	492	5	39	$67,938
2022	2,018	5	93	$259,082
2021	2,435	6	119	$282,375
2020	1,048	9	117	$135,034
2019	89	3	18	$6,589
2018	15	1	14	$983

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Long return visit (40+ min)	334	$53,469
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	77	$7,135
Service	49	$3,328
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	20	$2,634
Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service)	12	$1,372

2022

Sort by

Largest Medicaid services in 2022

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	854	$142,995
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	733	$62,025
Long return visit (40+ min)	221	$40,037
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	170	$12,975
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	40	$1,050

2021

Sort by

Largest Medicaid services in 2021

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1,023	$165,206
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	966	$85,481
Long return visit (40+ min)	138	$21,389
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	238	$7,236
Telehealth originating site facility fee	30	$1,547
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	40	$1,516

2020

Sort by

Largest Medicaid services in 2020

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	542	$98,765
Long return visit (40+ min)	117	$11,874
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	105	$10,576
Telehealth originating site facility fee	132	$7,470
Return visit (30+ min)	30	$2,657
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	19	$1,405
OFF/OP EST MAY X REQ PHY/QHP	40	$1,140
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	27	$616
Telehealth transmission, per minute, professional services bill separately	36	$531

2019

Sort by

Largest Medicaid services in 2019

Long return visit (40+ min)	59	$5,393
Return visit (30+ min)	15	$697
OFF/OP EST MAY X REQ PHY/QHP	15	$499

2018

Sort by

Largest Medicaid services in 2018

Long return visit (40+ min)	15	$983

Drugs they prescribed that Part D paid

$1,147,973

Pharmacies billed $1,147,973 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 1% of their Part D prescriptions (13 of 1,260) in 2024. Above the middle of the specialty; the typical infectious disease clinician is at 0%.

849 generic and fewer than 11 brand-name prescriptions · $1,147,973 in drug cost · 31 antibiotic prescriptions to 13 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Biktarvy	93	$381,119	$4,098
Genvoya	44	$177,057	$4,024
Triumeq	37	$162,537	$4,393
Tivicay	40	$99,440	$2,486
Pifeltro	16	$33,687	$2,105

See all 38 drugs

Sort by

Every Part D drug this clinician prescribed

Biktarvy	93	$381,119	$4,098
Genvoya	44	$177,057	$4,024
Triumeq	37	$162,537	$4,393
Tivicay	40	$99,440	$2,486
Pifeltro	16	$33,687	$2,105
Descovy	13	$27,991	$2,153
Isentress	12	$23,576	$1,965
Maraviroc	13	$10,739	$826
Ozempic	11	$10,516	$956
Buprenorphine-Naloxone	20	$4,639	$232
Testosterone	20	$4,082	$204
Carvedilol Er	21	$2,528	$120
Valacyclovir	18	$846	$47
Rosuvastatin	20	$484	$24
Albuterol Sulfate Hfa	19	$449	$24
Pregabalin	22	$354	$16
Duloxetine	11	$351	$32
Fluocinonide	13	$260	$20
Atorvastatin	65	$240	$4
Metoprolol	17	$238	$14
Tamsulosin	21	$231	$11
Gabapentin	19	$204	$11
Fluticasone Propionate	19	$202	$11
Omeprazole	25	$181	$7
Metformin Hcl Er	27	$176	$7
Trazodone	23	$164	$7
Lisinopril	43	$147	$3
Amlodipine Besylate	25	$98	$4
Venlafaxine Hcl Er	16	$94	$6
Levothyroxine	16	$91	$6
Benazepril	17	$71	$4
Sulfamethoxazole-Trimethoprim	12	$67	$6
Alendronate	12	$66	$6
Losartan	14	$60	$4
Montelukast	13	$57	$4
Zolpidem	14	$40	$3
Acyclovir	11	$37	$3
Hydrochlorothiazide	17	$11	$1

Year by year

Sort by

Part D prescribing by year

2024	1,260	68	1% (13)	None	$1,147,973
2023	737	50	4% (28)	None	$735,800
2022	880	45	7% (62)	None	$766,485
2021	550	49	4% (22)	None	$483,277
2020	898	54	4% (33)	None	$838,825
2019	768	86	4% (27)	None	$570,640
2018	595	116	7% (40)	37%	$580,510
2017	937	146	2% (15)	None	$1,223,783
2016	708	106	4% (30)	50%	$1,727,451
2015	334	70	4% (14)	39%	$236,480
2014	12	None	0% (0)	None	$164
2013	220	12	None	None	$9,957

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 20 drugs

Sort by

Part D drugs prescribed in 2023

Biktarvy	76	$310,919	$4,091
Triumeq	32	$137,880	$4,309
Genvoya	21	$80,051	$3,812
Tivicay	15	$34,528	$2,302
Descovy	14	$32,648	$2,332
Isentress	12	$24,762	$2,063
Carvedilol Er	12	$2,610	$218
Duloxetine	18	$904	$50
Metoprolol	24	$524	$22
Pregabalin	11	$401	$36
Atorvastatin	31	$313	$10
Lisinopril	28	$291	$10
Zolpidem	12	$290	$24
Amlodipine Besylate	13	$199	$15
Metformin Hcl Er	11	$177	$16
Mirtazapine	11	$167	$15
Venlafaxine Hcl Er	11	$141	$13
Amlodipine Besylate-Benazepril	17	$123	$7
Oxycodone	11	$107	$10
Benazepril	13	$77	$6

2022: 22 drugs

Sort by

Part D drugs prescribed in 2022

Biktarvy	60	$238,875	$3,981
Triumeq	58	$228,467	$3,939
Genvoya	30	$112,190	$3,740
Pifeltro	13	$22,061	$1,697
Oxycontin	11	$8,616	$783
Testosterone	20	$6,111	$306
Advair Diskus	11	$4,683	$426
Temazepam	12	$1,763	$147
Pregabalin	21	$1,635	$78
Rosuvastatin	30	$1,146	$38
Dapsone	12	$439	$37
Atorvastatin	32	$411	$13
Oxycodone	26	$345	$13
Metoprolol	18	$318	$18
Bupropion Xl	11	$261	$24
Amlodipine Besylate	27	$236	$9
Metformin Hcl Er	30	$217	$7
Hydrocodone-Acetaminophen	11	$168	$15
Lisinopril	27	$153	$6
Mirtazapine	12	$107	$9
Amlodipine Besylate-Benazepril	20	$105	$5
Losartan	19	$83	$4

2021: 16 drugs

Sort by

Part D drugs prescribed in 2021

Triumeq	32	$120,435	$3,764
Biktarvy	35	$113,471	$3,242
Symtuza	19	$79,057	$4,161
Prezista	14	$27,201	$1,943
Efavirenz-Emtric-Tenofov Disop	11	$16,098	$1,463
Abacavir-Lamivudine	12	$1,931	$161
Acyclovir	24	$217	$9
Gabapentin	13	$178	$14
Atorvastatin	19	$162	$9
Omeprazole	15	$153	$10
Lisinopril	19	$118	$6
Amlodipine Besylate	18	$87	$5
Metformin Hcl Er	23	$77	$3
Pravastatin	12	$66	$5
Losartan	11	$37	$3
Metformin	16	$35	$2

2020: 33 drugs

Sort by

Part D drugs prescribed in 2020

Biktarvy	78	$265,220	$3,400
Triumeq	38	$155,390	$4,089
Genvoya	33	$108,937	$3,301
Symtuza	19	$71,738	$3,776
Descovy	21	$39,387	$1,876
Prezista	22	$38,882	$1,767
Isentress	18	$30,789	$1,710
Tivicay	17	$30,444	$1,791
Intelence	13	$18,559	$1,428
Victoza 2-Pak	18	$11,244	$625
Incruse Ellipta	13	$4,630	$356
Lidocaine	28	$3,636	$130
Valacyclovir	12	$1,131	$94
Abacavir-Lamivudine	13	$1,002	$77
Ventolin Hfa	11	$634	$58
Losartan-Hydrochlorothiazide	14	$515	$37
Rosuvastatin	14	$397	$28
Gabapentin	20	$283	$14
Acyclovir	23	$254	$11
Atorvastatin	28	$243	$9
Mirtazapine	11	$204	$19
Duloxetine	13	$202	$16
Metformin Hcl Er	25	$194	$8
Tramadol	15	$165	$11
Hydrocodone-Acetaminophen	12	$152	$13
Zolpidem	15	$128	$9
Omeprazole	15	$114	$8
Trazodone	16	$112	$7
Lisinopril	22	$99	$5
Pravastatin	14	$89	$6
Levocetirizine Dihydrochloride	12	$60	$5
Amlodipine Besylate	23	$45	$2
Metformin	13	$18	$1

2019: 20 drugs

Sort by

Part D drugs prescribed in 2019

Biktarvy	56	$188,762	$3,371
Triumeq	25	$74,664	$2,987
Genvoya	18	$55,157	$3,064
Descovy	24	$43,356	$1,806
Tivicay	21	$37,555	$1,788
Prezista	15	$24,994	$1,666
Doxycycline Hyclate	30	$3,381	$113
Lidocaine	12	$979	$82
Doxycycline Monohydrate	19	$805	$42
Valacyclovir	13	$747	$57
Sulfamethoxazole-Trimethoprim	30	$698	$23
Ventolin Hfa	12	$677	$56
Fluconazole	13	$353	$27
Acyclovir	20	$336	$17
Atorvastatin	18	$287	$16
Tamsulosin	14	$210	$15
Gabapentin	16	$191	$12
Amlodipine Besylate	19	$115	$6
Tramadol	11	$113	$10
Lisinopril	16	$109	$7

2018: 18 drugs

Sort by

Part D drugs prescribed in 2018

Genvoya	24	$68,242	$2,843
Truvada	19	$38,235	$2,012
Tivicay	21	$35,642	$1,697
Triumeq	11	$28,824	$2,620
Descovy	13	$21,999	$1,692
Lyrica	11	$5,848	$532
Symbicort	11	$3,653	$332
Doxycycline Hyclate	18	$1,086	$60
Fluconazole	15	$1,043	$70
Hydroxychloroquine Sulfate	12	$891	$74
Rifampin	13	$756	$58
Azithromycin	14	$629	$45
Doxycycline Monohydrate	12	$360	$30
Sulfamethoxazole-Trimethoprim	15	$276	$18
Oxycodone	13	$268	$21
Acyclovir	19	$264	$14
Pravastatin	25	$228	$9
Hydrocodone-Acetaminophen	11	$202	$18

2017: 22 drugs

Sort by

Part D drugs prescribed in 2017

Genvoya	60	$164,667	$2,744
Triumeq	44	$111,856	$2,542
Descovy	52	$83,092	$1,598
Tivicay	34	$52,989	$1,559
Truvada	31	$51,616	$1,665
Prezista	19	$27,339	$1,439
Prezcobix	16	$26,710	$1,669
Moxifloxacin	12	$3,125	$260
Doxycycline Hyclate	19	$1,744	$92
Azithromycin	11	$1,299	$118
Naloxone	18	$1,094	$61
Ketoconazole	11	$341	$31
Sulfamethoxazole-Trimethoprim	24	$292	$12
Acyclovir	44	$272	$6
Metoprolol	18	$250	$14
Pravastatin	26	$187	$7
Levothyroxine	15	$184	$12
Nevirapine	13	$136	$10
Tamsulosin	14	$134	$10
Isoniazid	12	$81	$7
Alendronate	11	$40	$4
Metformin	13	$35	$3

2016: 20 drugs

Sort by

Part D drugs prescribed in 2016

Harvoni	24	$767,401	$31,975
Noxafil	14	$112,827	$8,059
Tivicay	57	$84,297	$1,479
Truvada	43	$63,339	$1,473
Triumeq	15	$36,363	$2,424
Prezista	17	$22,989	$1,352
Prezcobix	14	$21,703	$1,550
Epzicom	13	$16,698	$1,284
Isentress	11	$14,350	$1,305
Edurant	11	$9,246	$841
Norvir	16	$4,108	$257
Moxifloxacin	12	$2,539	$212
Azithromycin	14	$903	$64
Sulfamethoxazole-Trimethoprim	32	$375	$12
Gabapentin	11	$322	$29
Acyclovir	17	$173	$10
Mirtazapine	12	$131	$11
Isoniazid	11	$95	$9
Amlodipine Besylate	12	$46	$4
Metformin	13	$28	$2

2015: 2 drugs

Sort by

Part D drugs prescribed in 2015

Norvir	13	$4,637	$357
Benazepril	14	$69	$5

2013: 6 drugs

Sort by

Part D drugs prescribed in 2013

Metoprolol	30	$1,127	$38
Simvastatin	26	$213	$8
Lisinopril	26	$170	$7
Metformin	18	$131	$7
Amlodipine Besylate	13	$80	$6
Hydrochlorothiazide	12	$46	$4

Money from drug and device companies

$121 in 2023

Sort by

Industry payments by year

2023	2	5	None	$121
2019	3	13	None	$192

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

ViiV Healthcare	Apretude	$79	3 payments Meals for Apretude · 2023-09-14 · $23 Meals · 2023-06-15 · $32 Meals for Apretude · 2023-05-02 · $25
Gilead Sciences	None	$42	2 payments Meals · 2023-10-06 · $25 Meals · 2023-02-10 · $17

See all 5 published payments

Sort by

Every published payment

Gilead Sciences	Meals · 2023-10-06	None	$25
ViiV Healthcare	Meals · 2023-09-14	Apretude	$23
ViiV Healthcare	Meals · 2023-06-15	None	$32
ViiV Healthcare	Meals · 2023-05-02	Apretude	$25
Gilead Sciences	Meals · 2023-02-10	None	$17

See earlier years (2019)

2019: $192

Sort by

Payments by company in 2019

Janssen Biotech	Symtuza	$118	9 payments Meals for Symtuza · 2019-08-23 · $12 Meals for Symtuza · 2019-07-26 · $14 Meals for Symtuza · 2019-06-28 · $14 Meals for Symtuza · 2019-05-24 · $15 Meals for Prezista · 2019-04-26 · $13 Meals for Symtuza · 2019-03-29 · $14 Meals for Symtuza · 2019-03-05 · $6 Meals for Symtuza · 2019-03-01 · $15 Meals for Symtuza · 2019-01-25 · $15
Gilead Sciences	None	$55	3 payments Meals · 2019-11-21 · $21 Meals · 2019-09-19 · $19 Meals · 2019-07-18 · $15
Merck Sharp & Dohme	Isentress	$20	1 payment Meals for Isentress · 2019-02-14 · $20

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 74.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1962722439
Licence: CA A125322California A125322: Current · expires 2027-04-30
Trained: Temple University School of Medicine, 2010 · 16 years ago
Group: Regents of the University of California · University of California San Francisco
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207RI0200X (207RI0200X)
Mailing address: UCSF Infectious Diseases, 400 Parnassus Ave, 5th Floor, San Francisco, CA, 94143
NPI first listed: 2010-06-08
NPI last updated: 2015-02-02

This is when the NPI record was last certified, not a medical board exam.